TCL Archive Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study June 21, 2002
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
